The role of regulator Eha in Edwardsiella tarda pathogenesis and virulence gene transcription.

Edwardsiella tarda is a pathogen with a broad host range that infects both animals and humans. Eha is a new transcriptional regulator identified in ET13, which is involved in the bacterial hemolytic activity. This study explored the effect of the Eha in the pathogenesis of E. tarda and the transcriptional regulation of the bacterial virulence genes (eseC, fliC, pagC and fimA). Our results found that the virulence of the eha mutant was 2.5-fold less than the one of its wild ET13 by LD50 in a murine model of i.p. infection, and the bacterial loads of the mutant displayed a different profile from the one of the wild strain. Most significantly, the mice infected with the mutant have greatly reduced acute inflammation in the liver, spleen and kidney compared to the ones infected with the wild. We further demonstrated that eseC, fliC and pagC were regulated directly by the Eha with qRT-PCR and ß-Galactosidase assay, but fimA wasn't done. The promoter regions of the genes modulated and the cly gene reported before had been found to contain a common conserved motif by using software. In addition, we found that the wild strain was more toxic to RAW264.7 macrophages, and induced less the host cell apoptotic responses than the eha mutant did. Altogether, these data suggested that the Eha was required for the bacterial infection and the transcriptive regulation of the important virulence genes of E. tarda.

CYB561 is a potential therapeutic target for breast cancer and is associated with immune cell infiltration.

BACKGROUND: Breast cancer (BC), a common malignant tumor originating from the terminal ductal lobular unit of the breast, poses a substantial health risk to women. Previous studies have associated cytochrome b561 (CYB561) with a poor prognosis in BC; however, its underlying mechanism of this association remains unclear. METHODS: We investigated the expression of CYB561 mRNA in BC using databases such as The Cancer Genome Atlas, Gene Expression Omnibus, Tumor-Normal-Metastatic plot, and Kaplan-Meier plotter databases. The prognostic value of CYB561 protein in BC was assessed in relation to its expression levels in tumor tissue samples from 158 patients with BC. The effect of CYB561 on BC progression was confirmed using in vivo and in vitro experiments. The biological functions and related signaling pathways of CYB561 in BC were explored using gene microarray, Innovative Pathway, Gene Ontology enrichment, and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. The correlation between CYB561 and the BC tumor immune microenvironment was evaluated using the CIBERSORT algorithm and single-cell analysis and further validated through immunohistochemistry of serial sections. RESULTS: Our study demonstrated that upregulation of CYB561 expression predicted poor prognosis in patients with BC and that CYB561 knockdown inhibited the proliferation, migration, and invasive ability of BC cells in vitro. CYB561 knockdown inhibited BC tumor formation in vivo.CYB561 was observed to modulate downstream tropomyosin 1 expression. Furthermore, CYB561 expression was associated with macrophage M2 polarization in the BC immune microenvironment. CONCLUSIONS: Elevated CYB561 expression suggests a poor prognosis for patients with BC and is associated with macrophage M2 polarization in the BC microenvironment. Therefore, CYB561 could potentially serve as a therapeutic target for BC treatment.

RAB10 promotes breast cancer proliferation migration and invasion predicting a poor prognosis for breast cancer.

RAB10, a member of the small GTPase family, has complex biological functions, but its role in breast cancer (BC) remains unclear. The aim of this study was to investigate the relationship between RAB10's role in BC, its biological functions, and BC prognosis. An online database was used to analyze the correlation between differential expression of RAB10 in BC and prognosis. The results of immunohistochemical assays in clinical cohorts were combined with the database analysis. The chi-square test and COX regression were employed to analyze the correlation between RAB10 and pathological features of BC. MTT, Transwell, and wound healing assays were conducted to detect BC cell proliferation, invasion, and metastatic ability. Bioinformatics techniques were employed to explore the correlation between RAB10 and BC tumor immune cell infiltration, and to speculate the biological function of RAB10 in BC and related signaling pathways. Our findings suggest that RAB10 expression is elevated in BC and is associated with HER2 status, indicating a poor prognosis for BC patients. RAB10 can promote the proliferation, migration, and invasion ability of BC cells in vitro. RAB10 is also associated with BC immune cell infiltration and interacts with multiple signaling pathways. RAB10 is a potential biomarker or molecular target for BC.